Posted by Michael Wonder on 03 Jul 2017
Two cancer drug prices have already been hiked by 8% this year
3 July 2017 - Cancer drugs have already been criticised for too high price tags.
Two drug companies raised the price of cancer drugs last week for the second time this year.
Amgen raised the price of its Blincyto by 3.9% on Wednesday, according to Bernstein analyst Ronny Gal, and Teva Pharmaceutical Industries raised the price of its Treanda by 4.5% on Saturday. Both Blincyto and Treanda are leukaemia drugs, while Treanda is also approved for non-Hodgkin lymphoma.
